Biotech Values

[DewDiligence]

Thanks for the abstract, Aslan. Post-secretional modifications are possible with GTC/Pharming’s technology, but they are not needed for ATryn, specifically. GTC’s Dr Meade has stated that the slightly different ratio of the AT isoforms between ATryn and plasma AT favors ATryn to a small degree by improving its binding affinity to heparin. This may help and it can’t hurt, so no attempt to change the ratio of the isoforms is undertaken.